Release Date: 27/04/16 14:43 Summary: Third Supplementary Target's Statement-BRS.AX Price Sensitive: Yes Download Document 287.12KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%